Hetero Biopharma launched Rilast (Rituximab) in Mayanmar
Hetero Biopharma – the Biologics arm of Hetero Group has recently launched ‘Rilast’ (Rituximab) in Yangon, the largest city of Myanmar on 27th Oct’ 2018. Rilast is the second Biosimilar (Rituximab) in Myanmar and Bevaas (Bevacizumab) is also expected to be shortly. Spearheaded by Dr. Praveen Shetty (DGM, Global Clinical Strategy & Medico Marketing), and Mr. Rajeev Rawal, Executive Director ABC International Ltd – Hetero’s business partner in Myanmar – the product Rilast was launched in the presence of leading Haematologists & Oncologists. Mr. Gurmeet Singh Gill, Country Manager - Hetero Myanmar, – Mr. Ravindra Joshi Head Marketing – ABC International Myanmar were also present during the launch meeting cum CME.
Prof. Rai Mra President Myanmar Medical Association & Prof. Khin San Yin chaired the CME meeting, while Dr. Nyo Me May Thyn Associate Prof. Dept of Pathology University of Medicine -2, Yangon presented on “Role of Pathologist in theragnostic era of Lymphoma”. Dr Karthik S Udupa, Professor and HOD (Dept. Medical Oncology), Manipal Hospitals, India presented “Diffuse large B-Cell Lymphoma – Standard treatment protocols”.
Dr. Praveen Shetty emphasised on the company’s continued efforts in making complex and life-saving drugs affordable to patients around the world.
Hetero Biopharma is committed to creating awareness of Lymphomas in Myanmar under “Knowledge Beyond Borders” (KBB) initiative. Biosimilars being a new treatment option for various complex diseases and disorders, Hetero Biopharma believes that this type of initiatives will help doctors to understand the importance of biosimilars and their efficacy to treat patients